Table 3.
Survival and times to death for vaccination studies
| B. anthracis challenge strain | Challenge route | Vaccine | Survivala,c | MTTD (days)b,c |
|---|---|---|---|---|
| Ames | Intranasal | PBS/alhydrogel | 0/20 (0) | 3 |
| dcG9241 exosporium | 0/10 (0) | 3.5 | ||
| 569-UM20 FIS | 10/20 (50)*** | 11** | ||
| dcG9241 FIS | 11/20 (55)*** | 14*** | ||
| dcG9241 ΔbclA FIS | 8/10 (80)**** | 14*** | ||
| Intraperitoneal | PBS/alhydrogel | 2/20 (10) | 2 | |
| dcG9241 exosporium | 1/10 (10) | 3 | ||
| 569-UM20 FIS | 8/20 (40) | 3.5 | ||
| dcG9241 FIS | 12/20 (60)** | 14*** | ||
| dcG9241 ΔbclA FIS | 10/10 (100)**** | 14*** | ||
| Ames ΔbclA | Intranasal | PBS/alhydrogel | 0/10 (0) | 3 |
| dcG9241 exosporium | 0/10 (0) | 3 | ||
| 569-UM20 FIS | 4/10 (40) | 7.5* | ||
| dcG9241 FIS | 5/10 (50)* | 9.5* | ||
| dcG9241 ΔbclA FIS | 8/10 (80)** | 14*** | ||
| Intraperitoneal | PBS/alhydrogel | 0/10 (0) | 2 | |
| dcG9241 exosporium | 0/10 (0) | 2.5 | ||
| 569-UM20 FIS | 7/10 (70)** | 14** | ||
| dcG9241 FIS | 9/10 (90)*** | 14*** | ||
| dcG9241 ΔbclA FIS | 9/10 (90)*** | 14*** |
a
Number of survivors/number challenged (percent survival).
b
MTTD, median time to death.
c
Values that are statistically different from that for the PBS/alhydrogel group are indicated by asterisks (****, P < 0.0001; ***, P < 0.001; **, P < 0.01; and *, P < 0.05).